Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.78 |
| ▸ | SLC5A1 | P13866 | 13/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18264981 | 0.90 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL17189293 | 0.90 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3438615 | 0.90 | SLC5A2 (0.77) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL19620437 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18685100 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611990 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13979845 | 0.88 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL12285684 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL18573839 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL9611971 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009143020-A1 | METHOD FOR TREATING HYPERURICEMIA EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143021-A1 | METHOD FOR TREATING AND PREVENTING KIDNEY STONES EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITION CONTAINING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009117367-A1 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008144346-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |